North America Biomaterials Market

North America Biomaterials Market Size (2024 to 2032)

The North American biomaterials market size is predicted to be USD 49.59 billion in 2024 and USD 144.77 billion by 2032, growing at a CAGR of 14.33% during the forecast period, acting as a top-performing region in the global biomaterials market.

In a short period, many patients worldwide have the quality of their lives improved with the aid of some implanted device.

The materials from which these devices are built include metals, ceramics, polymers, and an array of composites. As we reach the end of the 20th century, the success of using these materials is increasing, both because of improved surgical skills, and an improved understanding of how the body interacts with such devices.The rise in the research and development institutes to develop innovative procedures in the medical sector is lavishing the market's demand extensively. In addition, biomaterials play a significant role in repairing or replacing a tissue function of the body, which is also an attribute fuelling the market's growth. Besides, the growing prevalence of novel biomaterials and their developments makes the shares of the market expansion in North America. Furthermore, increasing beauty consciousness and increasing preference for plastic surgery are leveraging the growth of the market.

Growing demand for effective treatment or diagnostic procedures in the medical sector is a significant factor anticipated to surge growth opportunities for the market. In addition, increasing incidences of chronic diseases and other infectious diseases are creating chances for the market. Furthermore, a rise in funds from private and public organizations significantly influences the demand of the market. Also, increasing focus on introducing innovative products with the latest technology and ensuring better treatment procedures is ascribed to bolster the market's growth rate in this region.

However, the lack of knowledge of the best usage of the materials is slowly degrading the market's growth. The equipment in the laboratories requires massive amounts for installation and maintenance, which has remained a challenging attribute for the market participants in the North American biomaterials market. Stringent rules and regulations by the government in concern about patient health conditions are limiting the market's growth.

This research report on the North American Biomaterials market has segmented and sub-segmented the North America biomaterials market into the following categories

North America Biomaterials Market Analysis By Material Type

• Ceramic
• Metallic
• Polymer
• Natural

North America Biomaterials Market Analysis By Application

• Orthopedic
• Dental
• Cardiovascular
• Plastic surgery
• Wound healing
• Ophthalmology
• Tissue engineering
• Neurological
• Others

North America Biomaterials Market Analysis By Region

• The United States
• Canada
• Rest of North America

Regionally, the U.S. biomaterials market holds the highest shares of the market from the past decade and continues the same growth in the forecast period.

A rise in capital income is one of the factors propelling the demand of the market. The increasing number of patients with cardiovascular problems is also likely to outshine the growth of the biomaterials market in the U.S.The Canadian biomaterials market is positioned second in the leading dominant shares with the rise in the scale of pharmaceutical companies. Growing investments by the government in the construction of hospitals are leveraging the growth of the market. Also, increasing demand to level up the quality of medical products is accelerating the market's need.

KEY MARKET PLAYERS

A few of the promising companies operating in the North American biomaterials market are DSM, Zimmer Biomet Holdings, Inc., Evonik Industries AG, Wright Medical Technology, Inc., Corbion N.V., Berkeley Advanced Biomaterials, Bayer AG, Carpenter Technology Corporation, Covalon Technologies Ltd., BASF SE, Invibio Ltd., Inc., CAM Bioceramics BV and Collagen Matrix, Inc.